



First baby



First home/apartment



First interview



Their first insulin

FIRST TIMES CAN BE CHALLENGING.

A patient's first experiences with basal insulin is no exception.

BASAGLAR® patient support tools were designed with the practical aspects of initiating insulin in mind and may help your patients from their first step through to "it's part of my routine."

BASAGLAR is a recombinant human insulin analogue indicated:

- For once-daily subcutaneous administration in the treatment of patients over 17 years of age with type 1 or type 2 diabetes who require basal (long-acting) insulin for the control of hyperglycemia.
- In the treatment of pediatric patients (>6 years old) with type 1 diabetes who require basal (long-acting) insulin for the control of hyperglycemia.





basaglar®
 insulin glargine injection
 (rDNA origin) 100 units/mL

Lilly


> Nearly a century of insulin firsts^{1,2*}

Our heritage is developing diabetes medicines



* Comparative clinical significance unknown.

> Sylvia[†]




- A1C level above 8.0 at the last two visits
- Insulin-naïve, understands why her doctor has prescribed insulin; would like support starting
- Is a compliant patient, consistently takes her medications, and tries to eat well and exercise
- Typically has regular schedule

> How can you **help your patients start** on their first basal insulin?

[†] Fictitious patient. May not be representative of all cases.

> Clinical profile of BASAGLAR® in type 2 diabetes³

Efficacy results for BASAGLAR® vs. Lantus® in T2D, non-inferiority confirmed using margins of both 0.3% and 0.4%



The safety profile of BASAGLAR® was consistent with that previously reported for Lantus®.

	BASAGLAR® (n=376)	Lantus® (n=380)
Adverse events, overall incidence	52.1%	48.4%
Adverse events reported in ≥3% of patients		
Nasopharyngitis	5.6%	5.8%
Upper respiratory tract infection	5.1%	3.9%
Diarrhea	2.4%	3.7%
Hypoglycemia incidence ^{ll}		
Total	79.4% (296 patients)	77.7% (292 patients)
Severe	0.5% (2 patients)	0.5% (2 patients)

T2D=type 2 diabetes mellitus.

See inside back cover for study parameters.

> BASAGLAR® devices

BASAGLAR® KwikPen®: A device you may be familiar with



A prefilled pen that was designed for ease of use

- Is short and portable^{4*}
- Helps provide a low, smooth injection force^{4†}
- Delivers BASAGLAR® in 1-unit dose increments
- Delivers the full dose in 5 seconds

SAVVIO™: A reusable insulin pen




BASAGLAR® is available in a 3 mL cartridge for use in a reusable pen injector.

- Short⁵
- Lightweight⁵
- Easy to use^{5Δ}
- Modern design⁵
- Accurate and durable

* Comparative clinical significance unknown.

See inside back cover for study parameters.

Resources for your patients starting BASAGLAR®



BASAGLAR® Getting Started Brochure

The Getting Started Brochure can help your patients start on BASAGLAR® by offering tips for patients new to basal insulin, and explaining complex topics in a friendly, casual way; designed to be easier to understand.



BASAGLAR® Ease-In Guide

The first few days on insulin may seem challenging, but they are very important. This guide was designed to support and guide patients through their first few days with BASAGLAR®.



Basaglar.ca: A new website for patients starting BASAGLAR®

Information and advice

- About BASAGLAR®, how it works and who it's for
- When and how to take BASAGLAR®
- Understanding blood sugar readings
- Tips for starting healthy routines for taking BASAGLAR®
- Answers to frequently asked questions about BASAGLAR®

Helpful videos

- BASAGLAR® Show-Me Series™
 - The Five-Second Rule
 - Do the 2U
 - Exploring Injection Sites
 - Pen Storage

And other useful tools and resources.

Conditions of clinical use:

Comparability between BASAGLAR and the reference product has been established based on comparative chemistry and manufacturing studies, comparative non-clinical studies, and comparative pharmacokinetic/pharmacodynamic (PK/PD) and clinical trials. Comparative PK/PD and clinical trials were carried out in healthy volunteers and in adult patients with type 1 or type 2 diabetes. The indication for pediatric type 1 diabetes (>6 years old) has been granted on the basis of similarity, demonstrated between BASAGLAR and the reference product, in product quality, mechanism of action, disease pathophysiology, safety profile, dosage regimen, and based on clinical experience with the reference products.

Contraindications:

- Patients hypersensitive to insulin glargine, or to any ingredient in the formulation or component of the container.

Most serious warnings and precautions:

Hypoglycemia is the most common adverse effect of insulin, including BASAGLAR. Glucose monitoring is recommended. Uncorrected hypoglycemic or hyperglycemic reactions can cause loss of consciousness, coma, or death. Changes to insulin should be made cautiously, under medical supervision.

Administration: Do not use for intravenous, intramuscular, or insulin pump administration. Do not mix with any other insulin or dilute with any other solution. Do not use if not water-clear and colourless, or if it has formed a deposit of solid particles on the wall of the cartridge.

Other relevant warnings and precautions:

- BASAGLAR must not be used for the treatment of diabetic ketoacidosis
- The time course of BASAGLAR action may vary in different individuals or at different times in the same individual
- Hypokalemia may occur with insulin therapies
- Stress or concomitant illness may change insulin requirements
- Insulin may cause sodium retention and edema
- Insulin administration may cause insulin antibodies to form
- Patients with human insulin antibodies are at risk of hypoglycemia and/or cross-reactivity
- Combination of a thiazolidinedione (TZD) and insulin is not indicated for the treatment of type 2 diabetes
- To avoid transmission of disease, a cartridge or prefilled syringe shall not be used by more than one person
- Instruct patients to always check the insulin label before each injection to avoid medication errors
- Use of too low insulin dosages or treatment discontinuation, especially in type 1 diabetes, may lead to hyperglycemia and diabetic ketoacidosis
- Lipodystrophy, other injection site reactions, and allergic reactions may occur
- Careful monitoring of glucose and dose adjustments may be necessary in patients with hepatic or renal dysfunction
- Abrupt improvement in glycemic control may be associated with temporary worsening of diabetic retinopathy
- Careful monitoring of glucose is recommended during pregnancy and immediately after delivery
- Use caution when administering BASAGLAR to nursing women
- Use caution when administering BASAGLAR to geriatric patients >65 years of age

- The presence of acromegaly, Cushing's Syndrome, hyperthyroidism, and pheochromocytoma can complicate the control of diabetes
- BASAGLAR cartridges should only be used with SAVVIO, LUXURA HD, LUXURA, and MEMOIR pens
- Patients should be advised to take precautions to avoid hypoglycemia while driving or operating machinery

For more information:

Please refer to the product monograph at www.lilly.ca/basaglarpm/en for important information relating to adverse events, drug interactions, and dosing information not discussed in this piece. The product monograph is also available by calling 1-888-545-5972.

Study parameters:

- ‡ A 24-week, multicentre, randomized, double-blind, non-inferiority, phase 3 study with a 4-week post-treatment follow-up to compare the efficacy and safety of BASAGLAR® and Lantus® administered in combination with ≥ 2 oral antihyperglycemic medications in adult patients with type 2 diabetes (N=756). Insulin-naïve patients were starting BASAGLAR® at 10 units once daily. For patients already on Lantus®, BASAGLAR® was initiated at the same dose as the patient's pre-study Lantus® dose. A patient-driven algorithm under investigator supervision was followed throughout the study. Baseline A1C: BASAGLAR®, 8.35; Lantus®, 8.31.
- § Only patients with nonmissing baseline value and ≥ 1 nonmissing postbaseline value of the response variable were included in the analysis. LS mean change from baseline values were adjusted for the design factors of the study; baseline values are unadjusted means.
- ¶ Change from baseline A1C was derived using mixed-effects model for repeated measures (MMRM) methodology.
- || The incidence (%) of patients with ≥ 1 hypoglycemic event per category during the study period.
- ◇ Prefilled insulin devices were measured for diameter at the cartridge holder and dose window, length and weight with cap attached, thumb reach at 30 and 60 units, and glide force and glide force variability.
- Δ Multicentre, randomized, two-period crossover, open-label, simulated injection study. 203 pen-naïve subjects evaluated SAVVIO™ and LUXURA®. The primary objective of this study was to determine the final pen preference in all subjects.

References: **1.** Rosenfeld L. Insulin: discovery and controversy. *Clin Chem.* 2002;48(12):2270-2288. **2.** Medical letter – NOC for Lilly insulins. Eli Lilly Canada, Inc. April 2019. **3.** BASAGLAR® Product Monograph, Eli Lilly Canada Inc., July 24, 2019. **4.** Ignaut DA, Opincar M, Lenox S. FlexPen and KwikPen Prefilled Insulin Devices: A Laboratory Evaluation of Ergonomic and Injection Force Characteristics. *J Diabetes Sci Technol.* 2008;2(3):533-537. **5.** Wong M, Abdulnabi R, Carey MA, Fu H. A randomized, cross-over comparison of preference between two reusable insulin pen devices in pen-naïve adults with diabetes. *Curr Med Res Opin.* 2013;29(5):465-473.



FIRST TIMES CAN BE CHALLENGING.

BASAGLAR® patient support tools were designed with the practical aspects of initiating insulin in mind.

> Consider BASAGLAR® for your first insulin choice

BASAGLAR®:



BASAGLAR® achieved A1C reductions similar to Lantus®³



BASAGLAR® demonstrated hypoglycemia incidence similar to Lantus®³



BASAGLAR® provides convenient, once-daily dosing in 2 easy-to-use insulin pens^{1,4,5#}



BASAGLAR® tools provide your patients with practical resources and support



#Clinical significance has not been established. Please see Product Monograph for complete dosing and administration instructions.

LANTUS is a registered trademark owned by Sanofi-Aventis. BASAGLAR is a biosimilar product to LANTUS. While both BASAGLAR and LANTUS are insulin glargine products, they have not been designated as bioequivalent.

BASAGLAR is a registered trademark owned by or licensed to Eli Lilly and Company, its subsidiaries or affiliates. © 2019, Eli Lilly and Company. All rights reserved.



basaglar®
insulin glargine injection
(rDNA origin) 100 units/mL